ONTELRIQ
Live / Registered — Registered (as of 30 Dec 2025)
What this means for you
Registered since 30 Dec 2025. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98648435
- Registration number
- 8082390
- Mark type
- Stylized text
- Filed
- 15 Jul 2024
- Published for opposition
- 04 Mar 2025
- Registered
- 30 Dec 2025
- Attorney of record
- Ben Natter
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for treating cancer, oncological diseases, rare diseases, namely, growth disorders, bone diseases, musculoskeletal diseases, namely, fibrodysplasia ossificans progressiva, connective tissue diseases, spinal cord diseases, fractures, sprains, cartilage injuries, rare chronic liver diseases and cholestatic diseases, liver diseases, respiratory diseases, cardiovascular diseases, immune disorders, namely autoimmune diseases, chronic liver diseases, gastrointestinal diseases, metabolic diseases, namely, diabetes, hypoglycemia, gout, osteoarthritis, muscular dystrophy and anemia, inflammatory diseases, namely, enteric disease and connective tissue inflammation, urological diseases, disorders and diseases of the genitourinary system, namely, infertility, urovaginal infections, bladder disorders and sexually transmitted diseases, diseases and disorders of precocious puberty, gynecological disorders, to stimulate human fertility, for the treatment of acromegaly and malignant tumors, hormonal disorders, endocrine system disorders, namely, growth and thyroid gland disorders, connective tissue diseases, blood disorders, hemophilia, gastrointestinal bleeding disorders, neurological diseases, namely, brain injuries, spinal cord injuries, epileptic disorders, Alzheimer's disease, Huntington's disease and cerebral palsy, musculoskeletal disorders, bone diseases, neuromuscular disorders, namely, muscular dystrophy, muscle dystonias and cervical dystonia, cerebral palsy, muscle spasticity, blepharospasm, migraine, for the treatment of pain, for the treatment of glabellar lines, facial wrinkles, for the treatment and prevention of skin diseases, facial asymmetry
Owner
- Ipsen Pharma, Paris, FR
- Ipsen Pharma, Paris, FR
- Ipsen Pharma, Boulogne-Billancourt, FR
Prosecution history
- 30 Dec 2025 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 30 Dec 2025 — REGISTERED-PRINCIPAL REGISTER
- 07 May 2025 — NOTICE OF ALLOWANCE CANCELLED
- 28 Aug 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 28 Aug 2025 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 28 Aug 2025 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 28 Aug 2025 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 28 Aug 2025 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
- 07 May 2025 — TEAS DELETE 1(B) BASIS RECEIVED
- 29 Apr 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 04 Mar 2025 — PUBLISHED FOR OPPOSITION
- 04 Mar 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 26 Feb 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 11 Feb 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 11 Feb 2025 — EXAMINER'S AMENDMENT ENTERED